Clarametyx Biosciences
Innovating Beyond Antibiotics to Fight Biofilm-associated Disease
Challenge
Serious bacterial infections is biofilm-driven
Serious bacterial infections, which are largely biofilm-driven, are driving the global threat of antimicrobial resistance. More antibiotics alone will not solve the problem.
Conventional antibiotics and innate immune effectors cannot effectively kill biofilm-residing bacteria. Biofilm-driven need for higher doses and repeated, prolonged use of antibiotics contributes to resistance. Recent WHO, Lancet and BIO reports cite major failures in antibiotic development and innovation.
Solution
A differentiated technology platform and approach with disruptive potential
Clarametyx's approach: Target the universal biofilm structure itself with therapeutics and vaccines to eliminate this defense mechanism and increase effectiveness of immune intervention and antibiotics to clear infections.
1. Enables Rapid Immune Intervention.
2. Dramatically Improves Susceptibility to Antibiotics.
3. Reduces Site-Specific Inflammation to Improve Recovery.
Impact
Game-changing science
1. Novel immune-enabling, pro-stewardship technology platform appliable to all bacterial biofilm-associated diseases.
2. Premise derived from groundbreaking discoveries in biofilm structure.
3. CMTX-101 therapeutic for pneumonia and cystic fibrosis complements front line antibiotics for superiority to SoC.
4. CMTX-301 broad-spectrum vaccine for otitis media addresse.
| In the News |
Congratulations to Clarametyx Biosciences for raising $33 Million Series A Financing to Advance Anti-Biofilm Biologics for Serious Bacterial Infections
Congratulations to Clarametyx Biosciences for raising $33 Million Series A Financing to Advance Anti-Biofilm Biologics for Serious Bacterial Infections
Get in touch
Contact us for more information about how we can help you invest in healthcare, biotech, climate tech, or advanced systems.